| Schedule Of Segment Reporting Information |
|
|
Consumer
Products Segments |
|
|
Specialty
Pharmaceutical Segment |
|
|
Consolidated Totals |
|
| Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| March 31, 2018: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
8,070,765 |
|
|
$ |
– |
|
|
$ |
8,070,765 |
|
| Gross profit |
|
|
5,561,903 |
|
|
|
– |
|
|
|
5,561,903 |
|
| Selling, general and administrative |
|
|
(4,726,584 |
) |
|
|
(14,009 |
) |
|
|
(4,740,593 |
) |
| Research and development |
|
|
(116,634 |
) |
|
|
(37,070 |
) |
|
|
(153,704 |
) |
| Operating loss |
|
$ |
718,685 |
|
|
$ |
(51,079 |
) |
|
$ |
667,606 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| March 31, 2017: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
3,764,191 |
|
|
$ |
– |
|
|
$ |
3,764,191 |
|
| Gross profit |
|
|
2,433,003 |
|
|
|
– |
|
|
|
2,433,003 |
|
| Gain on change in derivative liability |
|
|
210,600 |
|
|
|
– |
|
|
|
210,600 |
|
| Royalty buy-out |
|
|
– |
|
|
|
(2,432,000 |
) |
|
|
(2,432,000 |
) |
| Selling, general and administrative |
|
|
(3,605,177 |
) |
|
|
(71,533 |
) |
|
|
(3,676,710 |
) |
| Research and development |
|
|
(49,033 |
) |
|
|
(139,683 |
) |
|
|
(188,716 |
) |
| Operating loss |
|
$ |
(1,010,607 |
) |
|
$ |
(2,643,216 |
) |
|
$ |
(3,653,823 |
) |
|